PANE, CHIARA
 Distribuzione geografica
Continente #
NA - Nord America 672
EU - Europa 393
AS - Asia 196
AF - Africa 12
Continente sconosciuto - Info sul continente non disponibili 2
SA - Sud America 1
Totale 1.276
Nazione #
US - Stati Uniti d'America 665
IT - Italia 238
SG - Singapore 94
CN - Cina 67
NL - Olanda 44
IE - Irlanda 22
FI - Finlandia 17
DE - Germania 16
GB - Regno Unito 13
IN - India 13
CI - Costa d'Avorio 12
BG - Bulgaria 11
FR - Francia 8
CA - Canada 7
CH - Svizzera 4
HK - Hong Kong 4
JP - Giappone 4
PH - Filippine 4
SE - Svezia 4
TR - Turchia 4
UA - Ucraina 4
VN - Vietnam 4
BE - Belgio 3
MK - Macedonia 3
RU - Federazione Russa 3
AP - ???statistics.table.value.countryCode.AP??? 1
CO - Colombia 1
CZ - Repubblica Ceca 1
ES - Italia 1
EU - Europa 1
IR - Iran 1
PL - Polonia 1
UZ - Uzbekistan 1
Totale 1.276
Città #
Chandler 143
Singapore 72
Ashburn 67
Santa Clara 54
Amsterdam 40
Naples 31
Millbury 26
Beijing 25
Nanjing 24
Dearborn 18
Des Moines 18
Seattle 18
Napoli 17
Princeton 16
Nola 13
Boston 12
Sofia 11
Lawrence 10
Milan 10
Norwalk 10
Cava De' Tirreni 8
Gricignano di Aversa 7
Le Cannet 7
Wilmington 7
Pune 6
Rome 6
Helsinki 5
Monteforte Irpino 5
Padova 5
Dong Ket 4
Fairfield 4
Hong Kong 4
Izmir 4
Latina 4
Lviv 4
Ottawa 4
Redwood City 4
Torre Annunziata 4
Washington 4
Battipaglia 3
Bitola 3
Brussels 3
Dallas 3
Dublin 3
General Mariano Alvarez 3
Houston 3
Montecorvino Pugliano 3
Toronto 3
Verona 3
Acerra 2
Brusciano 2
Davis 2
Florence 2
Formia 2
London 2
Marano di Napoli 2
Marsala 2
Munich 2
Parma 2
Phoenix 2
Pisa 2
Pompei 2
Portici 2
Sassari 2
Secunderabad 2
Shenyang 2
Tianjin 2
Turin 2
Whitby 2
Aleksandrów Kujawski 1
Atlanta 1
Bern 1
Boardman 1
Capua 1
Caserta 1
Changchun 1
Clifton 1
Eboli 1
Esslingen am Neckar 1
Guangzhou 1
Gunzenhausen 1
Hebei 1
Hefei 1
High Point 1
Indiana 1
Jinan 1
Kolkata 1
Kronberg 1
Kunming 1
Lanzhou 1
Lappeenranta 1
Leawood 1
Lecce 1
Los Angeles 1
Madrid 1
Messina 1
Mumbai 1
Nanchang 1
Pasadena 1
Qinhuangdao 1
Totale 832
Nome #
Dimethyl Fumarate Mediates Nrf2-dependent Mitochondrial Biogenesis in Mice and Humans 63
Cerebellum and cognition in Friedreich ataxia: a voxel-based morphometry and volumetric MRI study 58
The use of medical-grade cannabis in patients non-responders to Nabiximols 57
A randomized controlled pilot trial of lithium in spinocerebellar ataxia type 2. 55
Lamivudine and fingolimod co-administration in two patients with multiple sclerosis and occult hepatitis B virus infection 55
Application of the p9NORM correction method to timed neuropsychological tests in Parkinson's disease and multiple system atrophy. 55
Emotion Recognition and Psychological Comorbidity in Friedreich’s Ataxia 54
Dimethyl fumarate dosing in humans increases frataxin expression: A potential therapy for Friedreich’s Ataxia 53
Screening for Fabry disease in a series of Parkinson’s disease patients and literature review 51
Long-term effect of epoetin alfa on clinical and biochemical markers in friedreich ataxia 48
The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests 48
A randomized clinical trial of lithium in multiple system atrophy. 47
Prevalence and features of non-motor symptoms in Wilson's disease 47
Peripheral markers of autophagy in polyglutamine diseases 46
Normalization of timed neuropsychological tests with the PATA rate and nine-hole pegboard tests 45
Adult normative values for the PATA Rate Test 45
Stability of erythropoietin repackaging in polypropylene syringes for clinical use 44
Mobitz type I and II atrioventricular blocks during fingolimod therapy 42
GAA-FGF14 ataxia (SCA27B): phenotypic profile, natural history progression and 4-aminopyridine treatment response 34
Fingolimod first dose safety in clinical practice. 34
The Multiple Faces of Spinocerebellar Ataxia type 2 30
Conventional MRI findings in hereditary degenerative ataxias: a pictorial review 30
Motor and non-motor features in Parkinson's Disease patients carrying GBA gene mutations 28
Othello syndrome in Parkinson's disease: a systematic review and report of a case series 28
Screening for RFC-1 pathological expansion in late-onset ataxias: a contribution to the differential diagnosis. 27
Dissociative Identity Disorder: Restoration of Executive Functions After Switch from Alter to Host Personality. 26
Correction to: Peripheral markers of autophagy in polyglutamine diseases (Neurological Sciences, (2018), 39, 1, (149-152), 10.1007/s10072-017-3156-6) 26
Safety and feasibility of upper limb cardiopulmonary exercise test in Friedreich ataxia 26
The C-Terminal Cross-linked Telopeptide of Type I Collagen (CTX-I) as a Potential Cardiomyopathy Biomarker in Friedreich Ataxia Patients 25
The use of medical grade cannabis in Italy for drug-resistant epilepsy: a case series 24
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial 21
Ataxia and Hypogonadism: a Review of the Associated Genes and Syndromes. 20
Rationale and protocol of a double-blind, randomized, placebo-controlled trial to test the efficacy, safety, and tolerability of dimethyl fumarate in Friedreich Ataxia (DMF-FA-201) 19
Efficacy of innovative therapies in myasthenia gravis: A systematic review, meta-analysis and network meta-analysis 13
A new genetic cause of spastic ataxia: the p.Glu415Lys variant in TUBA4A 12
Brain Structure and Degeneration Staging in Friedreich Ataxia: Magnetic Resonance Imaging Volumetrics from the ENIGMA-Ataxia Working Group 12
Nonvascular Parkinsonism in Fabry Disease: Results from Magnetic Resonance and Dopamine Transporter Imaging 5
Gradient of microstructural damage along the dentato‐thalamo‐cortical tract in Friedreich ataxia 1
Totale 1.354
Categoria #
all - tutte 6.566
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.566


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202075 0 0 0 0 0 4 21 5 4 26 14 1
2020/202142 5 0 1 9 0 4 2 2 8 0 6 5
2021/2022188 3 6 1 1 5 10 6 5 31 13 37 70
2022/2023344 36 37 13 19 40 33 9 28 58 52 16 3
2023/2024256 7 33 17 21 14 25 13 55 7 2 32 30
2024/2025241 51 31 9 30 63 57 0 0 0 0 0 0
Totale 1.354